Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519012 | 0.82 | ALDH1A1 (0.62) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2217122 | 0.81 | UBE2N (0.43) | ALDH1A1NOTUMMAPTKDM1A | |
| SCHEMBL16201993 | 0.80 | NOTUM (0.56) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL45043 | 0.77 | NOTUM (0.56) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14495367 | 0.77 | EPHX2 (0.57) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4251316 | 0.77 | MEN1 (0.54) | ALDH1A1MEN1MAPTKMT2AHTT | |
| Hydrochloric Acid SCHEMBL1082574 | 0.76 | NOTUM (0.55) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1060286 | 0.76 | P2RX7 (0.56) | ALDH1A1CYP2C9MEN1MAPTKMT2A | |
| SCHEMBL518725 | 0.75 | ALDH1A1 (0.64) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31174792 | 0.75 | NOTUM (0.51) | ALDH1A1NOTUMCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | ALDH1A1 1611/4885NOTUM 1379/4885CYP1A2 1825/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | ALDH1A1 1611/4885NOTUM 1379/4885CYP1A2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.